Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell transplantation - PHASAL-GA Study
This study, called PHASAL-GA, is for children and adults who are having a special type of transplant called an allogeneic hematopoietic stem cell transplant. This is a procedure where they receive healthy stem cells from a donor. The study focuses on a medicine called Thymoglobuline, which is given to prevent a complication called GvHD (Graft-versus-Host Disease), where the donor cells attack the patient's body. We are looking at how the body processes this medicine, specifically how much of it is present in the blood and for how long it stays there. This is important for doctors to understand so they can make sure patients get the most effective and safest dose of Thymoglobuline. It's a follow-up study to learn more about a medicine already in use.
At a glance
What is this study about?
This study, called PHASAL-GA, is looking into how a medicine called Thymoglobuline works in the bodies of children and adults who are having a stem cell transplant. A stem cell transplant is a treatment where a patient receives healthy blood-forming stem cells from a donor. This can be a life-saving treatment for many serious illnesses. However, sometimes the new donor cells can see the patient's body as 'foreign' and attack it. This serious problem is called Graft-versus-Host Disease, or GvHD.
To help prevent GvHD, patients are often given medicines like Thymoglobuline. This study is specifically designed to understand how much of this medicine is present in a patient's blood over time and how long it stays there. This is known as 'plasma exposure.' By carefully measuring this, doctors can get a better idea of how each patient's body handles the medicine. This information is very important because it helps doctors decide the best dose to give to make sure the medicine works effectively while keeping side effects to a minimum.
The main goal is to measure the medicine's levels in the blood, but we'll also be looking at other measurements to get a full picture of how it behaves. This is a 'Phase IV' study, which means the medicine is already approved and in use, and this research aims to gather more detailed information about its use in real-world patients to improve care in the future. It's about ensuring patients get the most out of their treatment.
Key takeaways
- Study examines how Thymoglobuline works in transplant patients.
- Aims to understand medicine levels in blood to improve dosing.
- For children and adults undergoing donor stem cell transplants.
- No extra treatments, just extra blood tests during routine care.
- Helps advance understanding of GvHD prevention and treatment.
Who may be eligible?
This study is open to both adults and children who are going to have a special type of transplant called an allogeneic hematopoietic stem cell transplant. This means you will be receiving stem cells from a donor, rather than your own cells.
To be considered for this study, you must be receiving Thymoglobuline as part of your transplant treatment. There are no upper age limits, so adults of all ages can be considered, as well as children. Both males and females are eligible to take part.
As with any study, your doctors will review your full medical history to make sure that taking part is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you having a stem cell transplant with cells from a donor?
- Will you be receiving Thymoglobuline as part of your transplant treatment?
- Are you comfortable having a few extra blood samples taken during your regular tests?
- Are you aged 18 or over, or are you a child whose parents/guardians are considering this for you?
What does participation involve?
If you decide to take part in this study, it won't involve any extra appointments or procedures beyond what you would already be having for your stem cell transplant. We will simply be collecting extra blood samples during your regular blood tests. These samples will be used to measure the levels of Thymoglobuline in your blood at different times.
You will continue to receive your Thymoglobuline medicine as prescribed by your transplant team. The study itself won't change your treatment plan. The duration of your participation will depend on how long your doctors need to monitor the medicine levels, which ties in with your standard transplant care. This will primarily involve collecting data during your initial transplant period.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a stem cell transplant?
It's a treatment where you receive healthy blood-forming cells from a donor to replace unhealthy ones.
What is GvHD?
GvHD stands for Graft-versus-Host Disease, which is when the new donor cells attack the patient's body after a transplant.
What is Thymoglobuline?
It's a medicine given to patients having a stem cell transplant to help prevent GvHD.
Will taking part change my treatment?
No, your treatment will remain exactly as prescribed by your doctors. This study just collects extra information.
Do I have to be an adult to join?
No, this study is open to both children and adults who are having an allogeneic stem cell transplant.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.